Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.
Type:
Grant
Filed:
January 30, 2009
Date of Patent:
November 12, 2013
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
October 8, 2013
Assignee:
Aenorasis SA Pharmaceuticals and Medical Devices
Inventors:
Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Type:
Grant
Filed:
September 24, 2010
Date of Patent:
October 8, 2013
Assignee:
Central Iowa Health System
Inventors:
Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Type:
Grant
Filed:
September 9, 2010
Date of Patent:
September 17, 2013
Assignee:
Central Iowa Health System
Inventors:
Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
Type:
Grant
Filed:
June 4, 2008
Date of Patent:
September 10, 2013
Assignee:
Hoffmann-La Roche, Inc.
Inventors:
Max Hasmann, Helmut Lenz, Werner Scheuer
Abstract: Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.
Type:
Grant
Filed:
September 4, 2009
Date of Patent:
September 3, 2013
Assignee:
University of Washington through its Center for Commercialization
Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.
Type:
Grant
Filed:
November 25, 2009
Date of Patent:
July 23, 2013
Assignee:
Academia Sinica
Inventors:
Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko Prijovic
Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
Type:
Grant
Filed:
June 1, 2007
Date of Patent:
July 16, 2013
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.
Type:
Grant
Filed:
April 20, 2010
Date of Patent:
July 16, 2013
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
Abstract: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.
Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.
Abstract: The invention relates to purified hemocyanins, subunits or immunogenic fragments thereof, wherein the hemocyanins are purified from a hemolymph of Fissurella latimarginata (black limpet), Fissurella cumingi (strawberry limpet), or Fissurella maxima (queen limpet). The invention also relates to compositions including the purified hemocyanins and methods of treating neoplastic diseases by administering such compositions.
Abstract: Disclosed herein are methods and compositions for determining the sensitivity or enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing cell death, apoptosis and/or growth arrest which may be used for tumor suppression.
Abstract: The invention relates to a method of screening a patient to identify and quantify risk of colorectal cancer, and thereby identify patients suitable for further invasive investigation such as a colonoscopy. The method employs auto-antibodies that are shown to correlate with colorectal cancer risk method and involves of assaying a biological sample from the individual for a combination of a plurality of biomarkers selected from SEQUENCE ID NO's: 1 to 12, where the combination of biomarkers is chosen such that detection of all biomarkers in the patient correlates to at least a 50% risk of the patient being positive for colorectal cancer. Detection of all of the combination of biomarkers indicates that the patient should undergo a colonoscopy. Kits for performing the method of the invention are also provided.
Type:
Grant
Filed:
September 26, 2008
Date of Patent:
April 23, 2013
Assignee:
Royal College of Surgeons in Ireland
Inventors:
Gregor Kijanka, Dermot Kenny, Elaine Kay